| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.69▲ | 3.69▲ | 3.68▲ | 3.68▲ | 3.46▲ |
| MA10 | 3.69▲ | 3.68▲ | 3.66▲ | 3.60▲ | 3.38▲ |
| MA20 | 3.68▲ | 3.65▲ | 3.62▲ | 3.42▲ | 3.66▲ |
| MA50 | 3.65▲ | 3.63▲ | 3.61▲ | 3.37▲ | 5.00▼ |
| MA100 | 3.62▲ | 3.60▲ | 3.50▲ | 3.84▼ | 4.29▼ |
| MA200 | 3.62▲ | 3.42▲ | 3.36▲ | 4.79▼ | 6.32▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.002▼ | 0.006▲ | 0.009▲ | 0.036▲ | 0.076▲ |
| RSI | 56.743▲ | 59.793▲ | 58.405▲ | 58.343▲ | 45.492▼ |
| STOCH | 75.000 | 59.028 | 71.554 | 63.072 | 54.109 |
| WILL %R | 0.000▲ | -23.077▲ | -15.000▲ | -31.284 | -25.210 |
| CCI | 44.267 | 65.983 | 81.071 | 90.490 | 73.945 |
|
Wednesday, February 13, 2019 01:13 PM
Feb. 13, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the ...
|
|
Monday, February 11, 2019 12:20 PM
Adverum Biotechnologies (NASDAQ:ADVM) has announced non-human private (NHP) long-term safety data of ADVM-022, gene therapy currently in phase 1 to treat wet age-related macular degeneration (wet ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 22/02/19 | 3.65 | 3.73 | 3.61 | 3.70 | 448,813 |
| 21/02/19 | 3.56 | 3.67 | 3.52 | 3.63 | 247,166 |
| 20/02/19 | 3.68 | 3.73 | 3.555 | 3.58 | 268,642 |
| 19/02/19 | 3.82 | 3.88 | 3.55 | 3.69 | 503,329 |
| 15/02/19 | 3.53 | 3.90 | 3.47 | 3.81 | 372,574 |
| 14/02/19 | 3.64 | 3.66 | 3.44 | 3.50 | 202,495 |
| 13/02/19 | 3.56 | 3.69 | 3.48 | 3.64 | 400,708 |
| 12/02/19 | 3.56 | 3.60 | 3.43 | 3.55 | 281,145 |
| 11/02/19 | 3.31 | 3.54 | 3.31 | 3.52 | 146,623 |
| 08/02/19 | 3.34 | 3.40 | 3.30 | 3.33 | 89,062 |
|
|
||||
|
|
||||
|
|
||||
|
|